RxDoctor Payments Data

Kathleen Newton, APRN

Nurse Practitioner · Fort Dodge, IANPI 1700305109

Payments from drug & device makers

$2,511in general payments, 2019–2025

Across 108 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$485
  • Boehringer Ingelheim$341
  • E.r. Squibb & Sons, L.L.C.$309
  • Johnson & Johnson$247
  • Pfizer$223
  • Novartis$214
  • plus $691 from 15 others

What the payments were for

  • Food & beverage$2,511100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,511 in reported general payments places this provider in the 90th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$85,380
Medicare patients
636
Services billed
1,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban350$408,674
XareltoRivaroxaban65$63,380
EntrestoSacubitril/Valsartan47$54,291
JardianceEmpagliflozin34$27,646
Repatha SureclickEvolocumab28$19,779
BrilintaTicagrelor11$10,009
Metoprolol Succinate396$5,895
Ranolazine ErRanolazine34$3,994
Potassium Chloride152$3,283
Atorvastatin Calcium387$3,148
Amiodarone Hcl41$2,678
Carvedilol329$2,612
ClopidogrelClopidogrel Bisulfate282$2,475
Isosorbide Mononitrate ErIsosorbide Mononitrate156$2,315
Losartan Potassium259$2,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$223$408,674350 claims
Johnson & JohnsonXarelto$247$63,38065 claims
NovartisEntresto$214$54,29147 claims
Boehringer IngelheimJardiance$341$27,64634 claims
AstraZenecaBrilinta$485$10,00911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in Fort Dodge

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →